Related Experiment Videos
[Molecular therapy of breast carcinoma in the advanced phase]
Abstract:
Conventional chemotherapy regimens for the treatment of breast cancer have limited efficacy and are associated with significant toxicity, highlighting the need for novel targeted therapies. Increased expression and activation of receptor tyrosine kinases frequently occurs in human breast carcinomas and, therefore, several clinical trials are currently evaluating therapies targeting these receptors. Therapeutic strategies include blockade of individual receptors with monoclonal antibodies (e.g., trastuzumab) and inhibition of tyrosine kinase function (e.g., gefitinib). Trastuzumab is the first agent that has been approved for patients with human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer. Other growth-factor targeted drugs are in clinical development such as STI-571, farnesyl-transferase inhibitors and antibodies directed at the insulin-like growth factor.
Insights
Novel targeted therapies are needed for breast cancer due to chemotherapy limitations. Receptor tyrosine kinase inhibitors and monoclonal antibodies, like trastuzumab for HER2-positive breast cancer, show promise.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Conventional chemotherapy for breast cancer exhibits limited efficacy and significant toxicity.
- Increased expression and activation of receptor tyrosine kinases (RTKs) are common in breast carcinomas.
- There is a critical need for novel, targeted therapeutic strategies.
Purpose of the Study:
- To review current and developing targeted therapies for breast cancer.
- To highlight the role of receptor tyrosine kinases in breast cancer progression.
- To discuss therapeutic strategies including receptor blockade and kinase inhibition.
Main Methods:
- Review of clinical trials evaluating therapies targeting receptor tyrosine kinases.
- Discussion of specific agents such as monoclonal antibodies and tyrosine kinase inhibitors.
- Examination of approved and investigational growth-factor targeted drugs.
Main Results:
- Trastuzumab is the first approved therapy for HER2-overexpressing breast cancer.
- Several receptor tyrosine kinase-targeted therapies are under clinical investigation.
- Monoclonal antibodies and tyrosine kinase inhibitors represent key therapeutic approaches.
Conclusions:
- Targeted therapies offer a promising alternative to conventional chemotherapy for breast cancer.
- Inhibition of receptor tyrosine kinases and their signaling pathways is a viable strategy.
- Further development of targeted agents like trastuzumab and others is crucial for improving patient outcomes.